Global IVD Market to Reach $81.83 Billion in 2026, China as Growth Engine

来源: Fortune Business Insights
链接: https://www.fortunebusinessinsights.com/zh/industry-reports/in-vitro-diagnostics-ivd-market-101443

# Market Overview

According to the latest report from Fortune Business Insights, the global In Vitro Diagnostics (IVD) market reached $77.73 billion in 2025, is projected to grow to $81.83 billion in 2026, and reach $135.65 billion by 2034, with a compound annual growth rate (CAGR) of 6.50% during the forecast period. North America dominates with a 37.70% market share in 2025, while the Asia-Pacific region is expected to be the fastest-growing market.

# Market Drivers

## Rising Chronic Disease Prevalence
The increasing prevalence of acute and chronic diseases, including cardiovascular, genetic, and nervous system disorders, is driving demand for IVD products. According to CDC data, tuberculosis cases in the US increased by 5% in 2022, reaching 8,300 cases. The global prevalence of chronic hepatitis B virus infection is approximately 3.2%, equivalent to 257 million cases.

## Population Aging
China’s population aged 60 and above is approximately 297 million. The elderly population’s increased susceptibility to health conditions such as liver diseases, hypertension, and cardiovascular diseases is expected to drive global IVD market growth.

## Shift to Molecular Diagnostics
Molecular diagnostics is one of the most dynamic technologies in the IVD industry. With the application of nucleic acid detection and other cellular biomarkers, healthcare providers can detect infectious diseases from small samples, and this high sensitivity is driving a global preference shift toward molecular diagnostic technologies.

## Technological Advancements
The rising penetration of Point-of-Care Testing (POCT) devices, with their advantages of low cost, convenience, speed, and high efficiency, is causing patient populations to increasingly prefer these tests.

# Regional Market Analysis

## North American Market
The North American market was valued at $29.33 billion in 2025 and will reach $30.92 billion in 2026. The presence of major companies such as Abbott, Thermo Fisher, BD, and Danaher, favorable government regulations, well-established diagnostic infrastructure, and adoption of technologically advanced diagnostic technologies are key drivers.

## Chinese Market
China’s population aged 60 and above exceeds 297 million. Population aging and increasing chronic disease burden are major drivers. Government initiatives to expand healthcare services and promote molecular testing have accelerated IVD adoption, particularly in oncology and infectious disease diagnostics.

## European Market
Europe is the second-largest market, led by Germany. Strong regulatory frameworks, mature healthcare systems, and increasing adoption of novel molecular and POCT diagnostic systems are key factors.

# Company Commentary

As a professional organic synthesis service provider and IVD raw material supplier, Wuhan Henrysintai is closely monitoring the rapid growth trend of the global IVD market. In particular, population aging and increasing chronic disease burden in the Chinese market create huge demand for high-performance IVD raw materials.

We are committed to helping partners gain advantages in the global diagnostic market competition through self-developed high-performance IVD raw materials, including chemiluminescence (CLIA) reagents, immunoassay raw materials, and molecular diagnostic reagents. Our high-purity synthesis technology can meet the growing quality requirements for IVD raw materials.

As an important promoter of domestic substitution, the IVD raw materials we provide not only meet international quality standards but also have cost advantages, helping domestic IVD enterprises reduce dependence on imported raw materials and become more competitive in the global market.